Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
EyePoint’s Duravyu Misses Phase 2 NPDR Trial Goal
EyePoint Pharmaceuticals announced the topline results from its phase 2 PAVIA clinical trial, which evaluated the efficacy of Duravyu (vorolanib intravitreal insert), formerly known as EYP-1901, in treating non-proliferative diabetic retinopathy (NPDR). The trial revealed that Duravyu did not achieve…
Early Patching Shows Promise for Lazy Eye Treatment
A recent study conducted by experts from the University of Leicester sheds light on a potentially more effective treatment approach for children with amblyopia, commonly known as lazy eye. Published in The Lancet, the study challenges the conventional method of…
Emmecell Completes Dosing in Key Corneal Edema Trial
Emmetrope Ophthalmics, a leader in cell-based therapies for severe eye diseases, today announced the completion of the final dose administration in its U.S. clinical trial for EO2002, targeting the treatment of corneal edema. EO2002 Advances Toward Phase 3 This milestone…
Inflammasome Therapeutics Begins GA Clinical Trial
Inflammasome Therapeutics has officially dosed the first patient in a pioneering clinical trial aimed at treating geographic atrophy (GA) resulting from age-related macular degeneration (AMD). This trial, a first-in-class study for a sustained release implant, is sponsored by the University…
How to Slow The Myopia In Children With Contact Lenses
Myopia, or short-sightedness, is one of the most common eye health issues in children and means that they can’t see objects that are far away, causing their vision to blur. Symptoms usually appear between the ages of 8 and 12…
Slowing The Myopia In Children With Contact Lenses
Are you prescribing contact lenses for myopia management? We ask this question at the start of every myopia management lecture we deliver. Over the past two years, we have gone from having audiences with no hands raised to now having…
Nanoscope Announces Positive Results in RP Treatment
Nanoscope Therapeutics announced positive topline results from the phase 2b RESTORE trial, evaluating MCO-010, a novel gene therapy aimed at treating severe vision loss caused by advanced retinitis pigmentosa (RP), irrespective of the genetic mutation causing the disease. RESTORE Trial…
Regeneron’s High-Dose Aflibercept Receives FDA Approval
Regeneron has received FDA approval for Eylea HD (aflibercept 8 mg) in a significant development anticipated to substantially extend dosing intervals for patients with retinal diseases such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).…
FDA Rejects Lytenava by Outlook Therapeutics for Wet AMD
Outlook Therapeutics announced that the FDA has issued a complete response letter (CRL) regarding the company’s Biologics License Application (BLA) for ONS-5010 (Lytenava). ONS-5010 is an investigative ophthalmic formulation of bevacizumab aimed at treating wet AMD. While the FDA recognized…
LumiThera Receives $2.3M NIH Grant for Dry AMD Trial
LumiThera has been granted a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH), totaling up to $2.3 million in funding over a span of 2 years. This NIH/NEI grant is geared towards supporting…